Navigation Links
DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
Date:8/4/2011

chotic market.  Zogenix will be responsible for the clinical development and commercialization of a proprietary, long-acting (once-monthly) injectable formulation of risperidone using DURECT's SABER controlled-release formulation technology in combination with Zogenix's DosePro® needle-free, subcutaneous drug delivery system.  DURECT will be responsible for non-clinical, formulation and CMC development activities and will be reimbursed by Zogenix for its research and development efforts on the product.  The existing long-acting injectable risperidone product, which achieved $1.5 billion in global net sales in 2010, requires twice-monthly, 2 mL intramuscular injections with a 21 gauge or larger needle.  Zogenix expects to initiate clinical studies for Relday in patients with schizophrenia in early 2012.  Under the terms of the agreement, Zogenix made an upfront payment of $2.25 million to DURECT in July, with the potential to pay DURECT up to an additional $103 million in future clinical, regulatory and commercial milestone payments based upon successful achievement of certain events.  Zogenix will have exclusive global rights to commercialize Relday and will pay DURECT a mid single-digit to low double-digit percentage royalty on net sales.


  • Feasibility Projects and Other Activities.  During the second quarter of 2011, we continued work on several feasibility projects as a means of demonstrating that our technologies can achieve the drug delivery objectives set forth by our collaborators and are worthy of further development.  The Zogenix program, described above, was one such project which has matured into a development and license agreement.Earnings Conference CallA live audio webcast of a conference call to discuss second quarter 2011 results will be broadcast live over the internet at 4:30 p.m. Eastern Time on August 4 and is available by accessing DURECT's homepage at


  • SOURCE DURECT Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
    2. DURECT to Present at the Jefferies Healthcare Conference
    3. DURECT Announces Resignation of Chief Medical Officer
    4. DURECT to Present at the UBS Global Specialty Pharmaceuticals Conference
    5. DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results in Chronic Low Back Pain
    6. DURECT to Present at Cowen and Company Health Care Conference
    7. DURECT Corporation Invites You to Join its Fourth Quarter 2010 Earnings Conference Call
    8. DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR™ (SABER™-Bupivacaine) and Amendment of the Nycomed Agreement
    9. DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product
    10. DURECT to Present at the BIO CEO & Investor Conference
    11. DURECT to Present at the Credit Suisse 2010 Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... September 18, 2014 According ... (Surface & Intravascular Systems- Warming & Cooling), Application ... (Surgeon & Anesthesiologist, Nursing & Paramedical Staff) - ... MarketsandMarkets, this report studies the global Temperature Management Market ... The market is expected to reach $2.5 Billion ...
    (Date:9/18/2014)... SAN ANTONIO, Texas , Sept. 18, 2014  Casen ... vessels, skin and muscles to harden.  His case is one ... (GVM) in the world.  The only hospital in ... few in the world, offering treatment with the dual wave-length ... in San Antonio . Using a laser ...
    (Date:9/18/2014)... , Sept. 18, 2014 Research ... "China PTCA Balloon Market Investment Report, 2014-2016" ... as a indispensable medical device in percutaneous coronary intervention ... stent, but also as a device for pre-/post-stent dilatations. ... related to that of PCI. As national ...
    Breaking Medicine Technology:Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3
    ... Medical Systems, a global developer of high-end ultrasound systems, ... number of clinical applications and ranked first or second ... KLAS  "Ultrasound 2011: Innovation on the Move" report. ... monitoring and reporting the performance of information technology and ...
    ... Suneva Medical, a privately-held aesthetic medical device ... aesthetics injectable business with approval from Health Canada ... dermal filler for nasolabial folds or smile line ... long-lasting treatment, Bellafill provides physicians the opportunity to ...
    Cached Medicine Technology:ZONARE Scores in Clinical Applications, Performance and Customer Support & Service in KLAS 2011 Ultrasound Report 2ZONARE Scores in Clinical Applications, Performance and Customer Support & Service in KLAS 2011 Ultrasound Report 3Suneva Medical Announces Canadian Approval of Bellafill™ 2
    (Date:9/18/2014)... HealthDay Reporter THURSDAY, Sept. ... that testosterone replacement therapy effectively treats normally sagging levels of ... Drug Administration advisory panel said Wednesday. The panel, from ... of the popular drugs and require drug makers to conduct ... according to Bloomberg News . "The whole idea ...
    (Date:9/18/2014)... led by Queen,s University professor Robert Campbell (Ophthalmology) has ... not helpful or necessary., Glaucoma is the most common ... 400,000 Canadians are afflicted with the disease, which is ... enough to damage the optic nerve. The optic nerve ... the brain and is a vital part of vision., ...
    (Date:9/18/2014)... In ecology, disease tolerance is ... and nail, but rather tolerate it to live (and survive) better ... the disease only progresses very slowly if at all ... Regoes, a senior scientist at ETH Zurich,s Institute of Theoretical Biology, ... whether there are infected people who are more tolerant of the ...
    (Date:9/18/2014)... It is almost time to park your ... healthier and happier kids. The South Florida Hyundai Dealers ... Annual Miami Children’s Hospital 5K Run/Walk. Its title sponsor ... , The 5K will take place on Saturday August 20th. ... Coral Gables City Hall located at 405 Biltmore Way. ...
    (Date:9/18/2014)... Pittsburgh, PA (PRWEB) September 18, 2014 ... oncologists from Allegheny Health Network has documented ... undergo both surgical removal of the tumors along with ... annual meeting of ASTRO (American Society for ... radiosurgery (SRS) uses numerous precisely focused radiation beams to ...
    Breaking Medicine News(10 mins):Health News:FDA Panel: Limit Testosterone Drug Use 2Health News:FDA Panel: Limit Testosterone Drug Use 3Health News:FDA Panel: Limit Testosterone Drug Use 4Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3
    ... , ATLANTA, Aug. 6 ... the launch of an Atlanta-based program aimed at improving ... Emory University,s Latino Diabetes Education Program and the Johnson ... diabetes education in Hispanic and African American populations and ...
    ... , , MOUNTAIN ... MAPP ) announced today the pricing of its previously announced public ... offering price of $9.70 per share. Net proceeds, after estimated underwriting ... MAP Pharmaceuticals has granted the underwriters of the offering a ...
    ... , , , ... Inc. (OTC Bulletin Board: CCEL), one of the largest and most ... proliferative ability of stem cells found in menstrual blood (known as ... Dalian, China. Data from an in vitro study show that MenSCs ...
    ... Puerto Ricans, Mexicans, study finds , WEDNESDAY, Aug. 5 (HealthDay ... the good life comes at a price: A new study ... , Living the American lifestyle is probably to blame, say ... , Of three Hispanic subgroups they studied -- Puerto Ricans, ...
    ... , ST. LOUIS, Aug. 6 ... improvement and cost savings results of the IMI program at ... Association (AHA) Leadership Summit. Kirk Mathews, CEO of IMI, and ... average three-month-trend results of $1,500 Cost-per-Case reduction as well as ...
    ... TAMPA, Fla., Aug. 6 Gold Standard/Elsevier ... launch of three MedCounselor consumer drug information modules for pharmacies ... how to take medications safely, assists in identifying unknown tablets ... are indispensable in helping to increase consumer compliance to their ...
    Cached Medicine News:Health News:AADE, Emory University and Johnson & Johnson Diabetes Institute Partner to Educate and Improve Access to Care for Atlanta-area Minorities with Diabetes 2Health News:AADE, Emory University and Johnson & Johnson Diabetes Institute Partner to Educate and Improve Access to Care for Atlanta-area Minorities with Diabetes 3Health News:AADE, Emory University and Johnson & Johnson Diabetes Institute Partner to Educate and Improve Access to Care for Atlanta-area Minorities with Diabetes 4Health News:MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock 2Health News:MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock 3Health News:Cryo-Cell to Present Novel Adult Stem Cell Research During 2009 China Medical Biotech Forum 2Health News:Cryo-Cell to Present Novel Adult Stem Cell Research During 2009 China Medical Biotech Forum 3Health News:Cryo-Cell to Present Novel Adult Stem Cell Research During 2009 China Medical Biotech Forum 4Health News:Living in U.S. May Raise Hispanics' Cancer Risk 2Health News:Living in U.S. May Raise Hispanics' Cancer Risk 3Health News:Inpatient Management, Inc. and Reid Hospital Achieve Performance Improvement and Cost Savings 2Health News:Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules 2Health News:Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules 3
    Titanium. Straight shafts with 6 mm platform and Pierse tips. Flat serrated handle with dull finish....
    Delicate strong curved serrated tips. Serrated handle with dull finish....
    1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
    Two 2.75 mm long tips separated 1 mm with 1 x 2 teeth. Serrated handle with dull finish....
    Medicine Products: